PD-L1 companion diagnostic for Merck’s Keytruda, 11/15

November 2015—Clarient Diagnostics will offer the FDA-approved PD-L1 companion diagnostic, which will help identify patients most likely to benefit from Merck’s lung cancer drug Keytruda.

With diagnostic analysis from Clarient, physicians will be able to understand the PD-L1 expression status for their patients with metastatic non-small cell lung cancer. Merck’s clinical trials suggest that the level of PD-L1 expression in a person’s tumor correlates with response to Keytruda.

To help identify eligible patients, Clarient will perform an FDA-approved assay that Merck developed with Dako. The assay (PD-L1 IHC 22C3 pharmDx) determines the expression status of the biomarker protein PD-L1 from a patient’s biopsy tissue sample and can identify those patients that will likely respond most effectively to Keytruda.

***Clarient Diagnostics**, 949-425-5700*